24Aug 2022
Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial

Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial

There is no standard follow‐up protocol for men with a negative evaluation with systematic biopsies (SB) and multiparametric (mp)MRI and a persistent clinical suspicion of prostate cancer (PCa). To assess the proportion of clinically significant (cs)PCa during follow‐up after negative SB followed by non‐suspicious mpMRI and persistent clinical suspicion of PCa compared to the general population. Following negative prior biopsy and non‐suspicious mpMRI the risk of csPCa is low. However, compared to the general population the risk of csPCa is increased despite the high negative predictive value (NPV) of mpMRI. More research focusing on biochemical and image‐guided risk‐adapted diagnostic surveillance strategies is warranted.

  • #urology

Like

Save

Share